- Home
- AHG vs AMRN Comparison
AHG vs AMRN Comparison
Compare AHG & AMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$1.35
HOLD
Current Price
$14.36
Company Overview
Basic Information| Metric | AHG | AMRN |
|---|---|---|
| Founded | 2013 | 1989 |
| Country | China | Ireland |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 812.8M | 339.8M |
| IPO Year | N/A | 1993 |
Fundamental Metrics
Financial Performance| Metric | AHG | AMRN |
|---|---|---|
| Price | $1.35 | $14.36 |
| Analyst Decision | | Strong Sell |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | 4.3K | ★ 83.6K |
| Earning Date | 12-15-2025 | 10-29-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $14,777,798.00 | ★ $226,733,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 512.09 | N/A |
| 52 Week Low | $0.82 | $7.08 |
| 52 Week High | $2.35 | $20.90 |
Technical Indicators
Market Signals| Indicator | AHG | AMRN |
|---|---|---|
| Relative Strength Index (RSI) | 40.86 | 35.29 |
| Support Level | $1.30 | $13.64 |
| Resistance Level | $1.42 | $14.67 |
| Average True Range (ATR) | 0.13 | 0.74 |
| MACD | -0.01 | -0.15 |
| Stochastic Oscillator | 26.47 | 24.21 |
Price Performance
Historical Comparison AHG
AMRN
About AHG Akso Health Group ADS
Akso Health Group is a social e-commerce platform based in China. The company collaborates with domestic e-commerce platforms and offers users a wide selection of high-quality and affordable products on its social e-commerce platform. It generates majority of the revenues from sale of medical devices business.
About AMRN Amarin Corporation plc
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.